High-throughput profiling for discovery of non-coding RNA biomarkers of lung disease.
In respiratory medicine there is a need for clinical biomarkers for diagnosis, prognosis and assessment of response to therapy. Noncoding RNA (ncRNA) is expressed in all human cells; two major classes - long ncRNA and microRNA - are detectable extracellularly in the circulation and other biofluids. Altered ncRNA expression is associated with lung disease; collectively this indicates that ncRNA represents a potential biomarker class. This article presents and compares existing platforms for detection and quantification of ncRNA, specifically hybridization, qRT-PCR and RNA sequencing, and outlines methods for data interpretation and normalization. Each approach has merits and shortcomings, which can affect the choice of method when embarking on a biomarker study. Biomarker properties and pre-analytical considerations for ncRNA profiling are also presented. Since a variety of profiling approaches are available, careful study and experimental design are important. Finally, challenges and goals for reliable, standardized high-throughput ncRNA profiling in biofluids as lung disease biomarkers are reviewed.
Funding
Royal College of Surgeons in Ireland Seed Fund
History
Comments
The Version of Scholarly Record of this Article is published in Expert Review of Molecular Diagnostics 2016, available online at: http://www.tandfonline.com/ DOI: 10.1586/14737159.2016.1122526Published Citation
McKiernan PJ, Greene CM. High-throughput profiling for discovery of non-coding RNA biomarkers of lung disease. Expert Review of Molecular Diagnostics. 2016;16(2):173-85Publication Date
2016-02-01External DOI
PubMed ID
26581119Department/Unit
- Beaumont Hospital
- Medicine